Abstract: Provided herein are chimeric adenoviral vectors. The provided chimeric adenoviral vectors can be used to induce a protective immune response and/or express a transgene in a subject in need thereof.

Abstract: The present application relates to recombinant adenoviruses, more in particular those that encounter low levels of pre-existing neutralizing activity in hosts that are in need of treatment or vaccination. Particularly, the invention relates to recombinant vectors derived from two subgroup D adenoviruses: Ad26 and Ad48.

Abstract: The invention relates to pharmaceutical compositions comprising replication-defective adenoviruses, said adenoviruses generally comprising an adenoviral genome wherein a heterologous nucleic acid of interest is incorporated, and wherein said nucleic acid typically encodes an antigen. Such compositions are suitable for vaccination purposes. The pharmaceutical compositions of the present invention further comprise an adjuvant, which stimulates and increases the immune response towards the antigen encoded by the heterologous nucleic acid. Preferred adjuvants are oil-emulsion based adjuvants and aluminium-based adjuvants.

Abstract: The present invention relates to methods of introducing an expressible non-viral nucleic acid sequence into a T lymphocyte cell, a B-cell, or a mast cell, comprising contacting the cell with a viral particle containing a modified viral coat proteins containing adenoviral amino acid sequence from an adenoviral serotype Ad35 or Ad51 fiber protein, arrays of subpopulations of cells made by such methods, and a method for a ex vivo transduction of a population of cells.

Abstract: The present invention relates to a method of introducing an expressible non-viral nucleic acid sequence into a cell having a common non-universal binding receptor and selected from T lymphocytes, B-, and mast cells, comprising contacting said cell with a viral vector comprising a recombinant nucleic acid sequence containing sequence for said expressible non-viral nucleic acid and comprising a modified viral coat consisting of native viral coat proteins and modified coat protein containing adenoviral amino acid sequence from an adenoviral serotype 35 or 51 fibre protein, wherein said adenoviral sequence of said modified protein is a ligand for said binding receptor. Alternatively said vector comprises a sequence coding for a viral capsid consisting of native adenoviral capsid proteins and modified capsid protein containing amino acid sequence from an adenoviral serotype other than the serotype of said native capsid proteins, wherein said modified protein is a ligand for said binding receptor.